The FDA is currently reviewing Medtronic's submission for its MiniMed 780G system, specifically regarding its use for Type 2 diabetes and label expansion into Europe.

2 reports, 2 independent Updated Jul 24

Gone quiet Reached 2 outlets in its first 24 hours

Reports: 2
Developments: 1
Repetition: 50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

The FDA is currently reviewing Medtronic's submission for its MiniMed 780G system, specifically regarding its use for Type 2 diabetes and label expansion into Europe.

Who's involved

What this event is mainly about

FDA

Keep exploring

Part of

FDA granted regulatory milestones to Medtronic, which is integrating with Abbott's Instinct sensor. All 2 developments

The entities involved

FDA
- InflaRx is seeking discussions with the FDA and collaborating with Staidson BioPharmaceuticals on clinical trials.14:20
- Teva's acquired product is currently undergoing review by the FDA.14:17

Related events

Both the FDA and the European Medicines Agency govern drug approval processes.Aug 12

Coverage

Newest first; wire copies grouped

Jul 24MedTech DiveMedtronic receives Type 2 label expansion for MiniMed 780G in Europe This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive
Jul 22Medical Device NetworkMedtronic’s MiniMed 780G system gains CE Mark for expanded indications Medtronic’s MiniMed 780G system has received European CE Mark approval to expand the indications for use by people aged two year